Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Sep;11(9):1522-8.
doi: 10.1016/j.jtho.2016.05.031. Epub 2016 Jun 11.

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

Ibiayi Dagogo-Jack  1 , Justin F Gainor  1 , Rebecca L Porter  1 , Katherine R Schultz  1 , Benjamin J Solomon  2 , Sara Stevens  1 , Christopher G Azzoli  1 , Lecia V Sequist  1 , Inga T Lennes  1 , Alice T Shaw  3
Affiliations

Clinicopathologic Features of NSCLC Diagnosed During Pregnancy or the Peripartum Period in the Era of Molecular Genotyping

Ibiayi Dagogo-Jack et al. J Thorac Oncol. 2016 Sep.

Abstract

Introduction: Cancer will be diagnosed in one in 1000 women during pregnancy. The outcomes of NSCLC diagnosed during pregnancy are dismal, with most patients dying within 1 year. Actionable mutations are more likely to be found among younger patients with NSCLC. However, most previous reports of NSCLC diagnosed during pregnancy did not include molecular genotyping.

Methods: We performed a retrospective analysis of patients seen at our institution between 2009 and 2015 to identify women in whom NSCLC was diagnosed during pregnancy or the peripartum period and determined clinicopathologic features, including molecular genotype.

Results: We identified 2422 women with NSCLC, including 160 women of reproductive age. Among the women of reproductive age, eight cases of NSCLC diagnosed during pregnancy or the peripartum period were identified; all were diagnosed in minimal or never-smokers with metastatic adenocarcinoma. Six of these patients were found to have anaplastic lymphoma kinase gene (ALK) rearrangements, whereas the remaining two were EGFR mutation positive. We observed a borderline significant association between a diagnosis of NSCLC during pregnancy or the peripartum period and ALK positivity (p = 0.053). All eight women in whom NSCLC was diagnosed during pregnancy or the peripartum period received treatment with genotype-directed therapies after delivery. The median overall survival has not been reached at a median follow-up of 30 months.

Conclusions: Although a diagnosis of NSCLC during pregnancy or the peripartum period is rare, diagnostic evaluation should not be delayed in pregnant women presenting with symptoms worrisome for lung cancer. Evaluation should include testing for targetable molecular alterations.

Keywords: ALK; EGFR; Lung cancer; Pregnancy.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Incidence of Pregnancy/Peripartum NSCLC at a Single Institution between 2009 and 2015
See this image and copyright information in PMC

Comment in

References

    1. Peccatori FA, Azim HA, Jr, Orecchia R, et al. Cancer, pregnancy, and fertility: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2013;6:160–70. - PubMed
    1. Boussios S, Han SN, Fruscio R, et al. Lung cancer in pregnancy: report of nine cases from an international collaborative study. Lung Cancer. 2013;82:499–505. - PubMed
    1. National Toxicology Program. NTP Monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy. NTP Monogr. 2013;2:i-214. - PubMed
    1. Azim HA, Peccatori FA, Pavlidis N. Lung cancer in the pregnant woman: to treat or not to treat, that is the question. Lung Cancer. 2010;67:251–6. - PubMed
    1. Pavlidis N. Lung cancer during pregnancy: an emerging issue. Lung Cancer. 2008;59:279–81. - PubMed

MeSH terms